English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Paclitaxel, administered as intravenous infusion currently, is an effective anticancer drug belonging to the taxane family (Figure 1) and used in the treatment of a wide variety of cancers including breast and ovarian cancers (Rowinsky et al., 1995). Researchers have been looking for more effective and convenient ways to administer paclitaxel with less formulation-related toxicities than the commercially available formulations like Taxol® by Bristol-Meyers Squibb. It is well known that some of the limitations of the current formulation come from Cremophor EL, a polyoxyethylated castor oil. This particular component is known to cause hypersensitivity (Weiss et al., 1990), to be responsible for nonlinear pharmacokinetic behavior (Kearns et al., 1995; Gianni, 1995) and to cause paclitaxel precipitation oftentimes when diluted during the infusion process (Pfeifer, 1993). Formulations for paclitaxel and its analogs have been prepared in many different ways for various administration procedures (Kim et al., 2006; Xie et al., 2007; Sugahara et al., 2007; Singla et al., 2002; Hennenfent & Govindan, 2006). Several years ago, Abraxane®, a suspension of albumin nanoparticles containing paclitaxel, obtained approval to treat metastatic breast cancer patients (Ibrahim et al., 2002; Garber, 2004). Abraxane®, a solvent-

Development, Optimization and Absorption Mechanism of DHP107, Oral Paclitaxel Formulation for Single-Agent Anticancer Therapy